Affordable Access

deepdyve-link
Publisher Website

Relevance of sentinel lymph node biopsy in early endometrial cancer: A series of 249 cases.

Authors
  • Jayot, Aude1
  • Owen, Clémentine2
  • Bendifallah, Sofiane3
  • Kolanska, Kamila2
  • Boudy, Anne-Sophie2
  • Touboul, Cyril4
  • Darai, Emile4
  • 1 Department of Gynecology and Obstetrics, Tenon University Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), Institut Universitaire de Cancérologie (IUC), Sorbonne University, Paris, France. Electronic address: [email protected] , (France)
  • 2 Department of Gynecology and Obstetrics, Tenon University Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), Institut Universitaire de Cancérologie (IUC), Sorbonne University, Paris, France. , (France)
  • 3 Department of Gynecology and Obstetrics, Tenon University Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), Institut Universitaire de Cancérologie (IUC), Sorbonne University, Paris, France; INSERM UMR_S 707, "Epidemiology, Information Systems, Modeling", Sorbonne University, Paris, France; INSERM UMR_S 938 Sorbonne University, Paris, France. , (France)
  • 4 Department of Gynecology and Obstetrics, Tenon University Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), Institut Universitaire de Cancérologie (IUC), Sorbonne University, Paris, France; INSERM UMR_S 938 Sorbonne University, Paris, France. , (France)
Type
Published Article
Journal
European journal of obstetrics, gynecology, and reproductive biology
Publication Date
Jan 11, 2021
Volume
258
Pages
208–215
Identifiers
DOI: 10.1016/j.ejogrb.2020.12.038
PMID: 33453523
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

We aimed to evaluate the impact of the sentinel lymph node (SLN) biopsy on adjuvant therapy, recurrence and survival in early endometrial cancer (EC). We retrospectively included all patients who underwent SLN biopsy for EC between February 2007 and March 2018. Of the 249 EC patients included, the overall SLN detection rate was 91 %. SLNs were positive in 36 (14.4 %) cases. Nine of the 13 preoperative low-risk patients with positive SLNs were re-operated and 22 % presented positive non-SLNs. No second surgery was required for the 10 patients upstaged to intermediate risk after negative SLN biopsy. Nine of the 11 preoperative intermediate-risk patients with positive SLNs were re-operated and 33 % presented positive non-SLNs. Eleven of the 24 preoperative high-risk patients with negative SLNs were re-operated and 27 % presented positive non-SLNs. For the whole population, 3-year overall survival was 99 % (CI 95 % (97-1)) and 3-year recurrence-free survival (RFS) was 92 % (CI 95 % (0.87-0.95)). Our study supports the feasibility of the SLN procedure for assessing risk recurrence in patients with early-stage EC. SLN biopsy should lead to major reductions in secondary staging and better adaptation of adjuvant therapy. Copyright © 2020. Published by Elsevier B.V.

Report this publication

Statistics

Seen <100 times